These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37266989)

  • 21. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
    Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 Mar; 62(1593):35-39. PubMed ID: 32555120
    [No Abstract]   [Full Text] [Related]  

  • 24. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
    Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
    J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
    Yaldo AZ; Wertz DA; Rupnow MF; Quimbo RM
    Clin Ther; 2008 Dec; 30(12):2452-60. PubMed ID: 19167603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current trends in migraine prophylaxis.
    Ramadan NM
    Headache; 2007 Apr; 47 Suppl 1():S52-7. PubMed ID: 17425710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CGRP antagonists for decreasing migraine frequency: New options, long overdue.
    Bucklan J; Ahmed Z
    Cleve Clin J Med; 2020 Apr; 87(4):211-218. PubMed ID: 32238376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topiramate for migraine prophylaxis.
    Drug Ther Bull; 2006 Aug; 44(8):62-4. PubMed ID: 16903488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
    CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).
    Garces F; Mohr C; Zhang L; Huang CS; Chen Q; King C; Xu C; Wang Z
    Cell Rep; 2020 Feb; 30(6):1714-1723.e6. PubMed ID: 32049005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medications Approved for Preventing Migraine Headaches.
    Spindler BL; Ryan M
    Am J Med; 2020 Jun; 133(6):664-667. PubMed ID: 32145209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018.
    Loder E; Rizzoli P
    Headache; 2018 Nov; 58 Suppl 3():218-229. PubMed ID: 30137671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.
    Mathew NT; Jaffri SF
    Headache; 2009; 49(10):1466-78. PubMed ID: 19912346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
    Alex A; Vaughn C; Rayhill M
    Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Migraine preventive treatment: monoclonal antibodies against calcitonine gene related peptide].
    Goicochea MT; Bonamico L
    Medicina (B Aires); 2021; 81(3):427-431. PubMed ID: 34137704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine.
    Khanal S; Underwood M; Naghdi S; Brown A; Duncan C; Matharu M; Mistry H
    J Headache Pain; 2022 Sep; 23(1):122. PubMed ID: 36114468
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.